Expression and Clinical Significance of TAp73alpha, P53, PCNA and Apoptosis in Hepatocellular Carcinoma

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2005 May 11

PMID 15884108

Citations 5

Authors

Hai-Xia Qin

Ke-Jun Nan

Guang Yang

Zhao Jing

Zhi-Ping Ruan

Chun-Li Li

Rui Xu

Hui Guo

Chen-Guang Sui

Yong-Chang Wei

Affiliations

Soon will be listed here.

Abstract

Aim: To study the prognostic role of TAp73alpha, p53, proliferating cell nuclear antigen (PCNA) and apoptosis in patients with hepatocellular carcinoma (HCC) after surgical tumor ablation.

Methods: Forty-seven human resected HCC tissues and 42 adjacent non-cancerous tissues were studied with 10 normal liver tissues as control group. TAp73alpha, p53, and PCNA were detected with Elivision immunohistochemistry. Terminal deoxynucleotidyl transferase (TdT)-mediated d-UTP-biotin nick-end labeling (TUNEL) method was used to detect the apoptosis cells. All clinical and pathological materials were analyzed by SPSS10.0 statistical package.

Results: TAp73alpha overexpressed in HCC tissues (36.2%) when compared with adjacent non-cancerous tissues (2.38%, P<0.005) and normal liver tissues (0, P<0.01). Mutant type p53 (mt-p53) overexpressed in HCC tissues (38.3%) when contracted with adjacent non-cancerous tissues (16.7%, P<0.05) and normal liver tissues (0, P<0.01). Proliferation index (PI) level in HCC tissues was significantly higher than that in adjacent non-cancerous tissues (30.34%+/-4.46% vs 27.88%+/-5.89%, t, P = 0.028). Apoptosis index (AI) level in HCC tissues was higher than that in adjacent non-cancerous tissues (8.62%+/-2.28% vs 7.38%+/-2.61%, t, P = 0.019). Expression of TAp73alpha was associated with lymph node metastasis and mt-p53, with r = 0.407 and 0.265, respectively. Expression of mt-p53 was associated with Edmondson's stage and AFP, with r = 0.295 and -0.357, respectively. In Kaplan-Meier univariant analysis, TAp73alpha, AFP, TNM stage, portal vein invasion, liver membrane invasion and HBsAg correlated with prognosis (log rank, P = 0.039, 0.012, 0.002, 0.000, 0.014, 0.007, respectively). Multivariant Cox regression analysis showed that TAp73alpha, AFP, TNM stage, portal vein invasion, liver membrane invasion and age were independent factors of prognosis.

Conclusion: These results suggest that TAp73alpha can be used as a prognostic indicator of patients with HCC undergoing surgical tumor ablation. AFP, TNM, portal vein invasion, liver membrane invasion and age also have a potency of predicting the prognosis of HCC.

Citing Articles

The clinical utility of the proliferating cell nuclear antigen expression in patients with hepatocellular carcinoma.

Ma S, Yang J, Li J, Song J Tumour Biol. 2015; 37(6):7405-12.

PMID: 26676639 DOI: 10.1007/s13277-015-4582-9.

Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival.

Niu Z, Niu X, Wang M World J Hepatol. 2015; 7(1):7-27.

PMID: 25624992 PMC: 4295195. DOI: 10.4254/wjh.v7.i1.7.

Prognostic significance of TP53 expression for patients with hepatocellular carcinoma: a meta-analysis.

Zhan P, Ji Y Hepatobiliary Surg Nutr. 2014; 3(1):11-7.

PMID: 24696834 PMC: 3954998. DOI: 10.3978/j.issn.2304-3881.2014.01.03.

TP53 immunohistochemical expression is associated with the poor outcome for hepatocellular carcinoma: evidence from a meta-analysis.

Ji Y, Wang Q, Xue J Tumour Biol. 2013; 35(2):1653-9.

PMID: 24078450 DOI: 10.1007/s13277-013-1228-7.

Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis.

Liu J, Ma Q, Zhang M, Wang X, Zhang D, Li W Eur J Cancer. 2012; 48(15):2328-38.

PMID: 22459764 PMC: 3395767. DOI: 10.1016/j.ejca.2012.03.001.

References

Matsumura I, Tanaka H, Kanakura Y . E2F1 and c-Myc in cell growth and death. Cell Cycle. 2003; 2(4):333-8. View

Landis S, Murray T, Bolden S, Wingo P . Cancer statistics, 1998. CA Cancer J Clin. 1998; 48(1):6-29. DOI: 10.3322/canjclin.48.1.6. View

Pan H, Liao S, Lai W, Lu H, Hsiao K . Overexpression but lack of mutation and methylation of p73 in hepatocellular carcinoma. Acta Oncol. 2003; 41(6):550-5. DOI: 10.1080/02841860214968. View

Ito Y, Matsuura N, Sakon M, Miyoshi E, Noda K, Takeda T . Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence. Hepatology. 1999; 30(1):90-9. DOI: 10.1002/hep.510300114. View

Willis A, Pipes T, Zhu J, Chen X . p73 can suppress the proliferation of cells that express mutant p53. Oncogene. 2003; 22(35):5481-95. DOI: 10.1038/sj.onc.1206505. View

Tannapfel A, Wasner M, Krause K, Geissler F, Katalinic A, Hauss J . Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma. J Natl Cancer Inst. 1999; 91(13):1154-8. DOI: 10.1093/jnci/91.13.1154. View

Irwin M, Marin M, Phillips A, Seelan R, Smith D, Liu W . Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature. 2000; 407(6804):645-8. DOI: 10.1038/35036614. View

Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G . p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell. 2003; 3(4):387-402. DOI: 10.1016/s1535-6108(03)00079-5. View

Momoi H, Okabe H, Kamikawa T, Satoh S, Ikai I, Yamamoto M . Comprehensive allelotyping of human intrahepatic cholangiocarcinoma. Clin Cancer Res. 2001; 7(9):2648-55. View

10.

Suda T, Isokawa O, Aoyagi Y, Nomoto M, Tsukada K, Shimizu T . Quantitation of telomerase activity in hepatocellular carcinoma: a possible aid for a prediction of recurrent diseases in the remnant liver. Hepatology. 1998; 27(2):402-6. DOI: 10.1002/hep.510270213. View

11.

Alonso M, Bello M, Gonzalez-Gomez P, Lomas J, Arjona D, De Campos J . Mutation analysis of the p73 gene in nonastrocytic brain tumours. Br J Cancer. 2001; 85(2):204-8. PMC: 2364057. DOI: 10.1054/bjoc.2001.1855. View

12.

Irwin M . Family feud in chemosensitvity: p73 and mutant p53. Cell Cycle. 2004; 3(3):319-23. View

13.

Itoh T, SHIRO T, Seki T, Nakagawa T, Wakabayashi M, Inoue K . Relationship between p53 overexpression and the proliferative activity in hepatocellular carcinoma. Int J Mol Med. 2000; 6(2):137-42. View

14.

Ebelt J, Neid M, Tannapfel A, Witzigmann H, Hauss J, Kockerling F . [Prognostic significance of proliferation markers in hepatocellular carcinoma (HCC)]. Zentralbl Chir. 2000; 125(7):597-601. View

15.

Endo K, Ueda T, Ohta T, Terada T . Protein expression of MDM2 and its clinicopathological relationships in human hepatocellular carcinoma. Liver. 2000; 20(3):209-15. DOI: 10.1034/j.1600-0676.2000.020003209.x. View

16.

Soini Y, Virkajarvi N, Lehto V, Paakko P . Hepatocellular carcinomas with a high proliferation index and a low degree of apoptosis and necrosis are associated with a shortened survival. Br J Cancer. 1996; 73(9):1025-30. PMC: 2074410. DOI: 10.1038/bjc.1996.199. View

17.

Cheng L, Wang S, Lin J . [Expression of phosphatase and tensin homology deleted on chromosome ten(PTEN) and p53 protein and their significance in human hepatocellular carcinomas]. Ai Zheng. 2003; 22(1):42-5. View

18.

Zemel R, Koren C, Bachmatove L, Avigad S, Kaganovsky E, Okon E . p73 overexpression and nuclear accumulation in hepatitis C virus-associated hepatocellular carcinoma. Dig Dis Sci. 2002; 47(4):716-22. DOI: 10.1023/a:1014767311799. View

19.

Tudzarova-Trajkovska S, Wesierska-Gadek J . Strong induction of p73 protein in vivo coincides with the onset of apoptosis in rat liver after treatment with the hepatocarcinogen N-nitrosomorpholine (NNM). J Cell Biochem. 2003; 90(4):837-55. DOI: 10.1002/jcb.10678. View

20.

Nakano A, Watanabe N, Nishizaki Y, Takashimizu S, Matsuzaki S . Immunohistochemical studies on the expression of P-glycoprotein and p53 in relation to histological differentiation and cell proliferation in hepatocellular carcinoma. Hepatol Res. 2003; 25(2):158-165. DOI: 10.1016/s1386-6346(02)00207-3. View